ダウンロード数: 1242
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| s00280-013-2151-8.pdf | 450.42 kB | Adobe PDF | 見る/開く |
| タイトル: | A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. |
| 著者: | Kanai, Masashi  Otsuka, Yoshihiko Otsuka, Kazunori Sato, Maremi Nishimura, Takafumi Mori, Yukiko  Kawaguchi, Michiya Hatano, Etsuro Kodama, Yuzo Matsumoto, Shigemi  https://orcid.org/0000-0001-6453-7489 (unconfirmed)Murakami, Yoshiki Imaizumi, Atsushi Chiba, Tsutomu Nishihira, Jun Shibata, Hiroyuki |
| 著者名の別形: | 金井, 雅史 |
| キーワード: | Curcumin Bioavailability Theracurmin® Gemcitabine Pancreatic cancer |
| 発行日: | Jun-2013 |
| 出版者: | Springer-Verlag |
| 誌名: | Cancer chemotherapy and pharmacology |
| 巻: | 71 |
| 号: | 6 |
| 開始ページ: | 1521 |
| 終了ページ: | 1530 |
| 抄録: | A growing number of preclinical studies have demonstrated that curcumin could be a promising anticancer drug; however, poor bioavailability has been the major obstacle for its clinical application. To overcome this problem, we developed a new form of curcumin (Theracurmin) and reported high plasma curcumin levels could be safely achieved after a single administration of Theracurmin in healthy volunteers. In this study, we aimed to evaluate the safety of repetitive administration of Theracurmin in cancer patients. |
| 著作権等: | The final publication is available at Springer via http://dx.doi.org/10.1007/s00280-013-2151-8 この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 This is not the published version. Please cite only the published version. |
| URI: | http://hdl.handle.net/2433/189888 |
| DOI(出版社版): | 10.1007/s00280-013-2151-8 |
| PubMed ID: | 23543271 |
| 出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。